| Primary Identifier | MGI:3057127 | Allele Type | Transgenic |
| Attribute String | Inducible, Reporter, Transactivator | Gene | Tg(Tek-rtTA,TRE-lacZ)1425Tpr |
| Strain of Origin | (C57BL/6 x CBA)F1 | Induced With | doxycycline/tetracycline |
| Is Recombinase | false | Is Wild Type | false |
| description | Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. In the presence of tetracycline or a tetracycline analog such as doxycycline, selective expression of beta-galactosidase is observed in the nuclei of vascular endothelium in a wide variety of tissues: aorta, heart, brain, lung, kidney, liver, spleen, uterus, prostate, stomach, skeletal muscle, large and small intestine. Expression is observed as early as embryonic day 9.5. In the absence of tetracycline, some beta-galactosidase expression occurs in the smaller branches of the aorta. A trend towards diminished beta-galactosidase expression when the alleles are crossed onto a C57BL/6 background has been reported. |
| molecularNote | Two transgenic constructs were co-injected into B6CBA fertilized oocytes. The first construct included a 2.1 kb endothelial-specific receptor tyrosine kinase (Tek) promoter fragment, the Tet-on transactivator, SV40 polyadenylation sequence, and a 1.7 kb enhancer sequence derived from Tek intron 1. The other construct consisted of a tetracycline-responsive element, nuclear-localizing beta-galactosidase gene, and a SV40 polyadenylation sequence. Although the transgenic constructs are closely linked in transgenic line 1425, no definitive evidence exists indicating that they have cointegrated. |
